

CHANGES TO COMPOSITION OF BOARD OF DIRECTORS AND BOARD COMMITTEES

Unless otherwise defined herein, all capitalised terms used in this announcement shall bear the same meanings given to them in the announcement dated 2 June 2015.

The Board of Directors of AsiaMedic Limited (the “**Company**”) wishes to announce that the sale and purchase of 95,431,396 ordinary shares representing approximately 28.15% of the issued and paid-up share capital of the Company by Grandiflora Pte. Ltd. and Mr Tan Wang Cheow to Luye Medicals Group Pte. Ltd. is completed today.

Following the Completion, the following changes to the Board of Directors will be effected:

- (a) The appointments of Dr Hong Hai (Independent Director); Mr Tan Soo Kiat (Non-Executive and Non-Independent Director); and Mr Koh Boon How, Kenneth (Non-Executive and Non-Independent Director) as Alternate Director to Mr Tan Soo Kiat, with effect from 3 June 2015; and
- (b) The stepping down of Mr Tan Wang Cheow as Non-Executive Chairman; Mr Andi Solaiman as Non-Executive Director; and Ms Suzanne Liau as Non-Executive Director, with effect from 3 June 2015.

The announcements, pursuant to Catalist Rule 704(6) of the Listing Manual (Section B: Rules of Catalist) of the SGX-ST (“**Catalist Rules**”), in relation to the appointment and cessation of the above Directors have been separately released to the SGX-ST.

The Board of Directors of the Company wishes to thank Mr Tan Wang Cheow, Mr Andi Solaiman and Ms Suzanne Liau for their contributions during their tenure as Directors of the Company.

Following the above changes, the composition of the Board of Directors and the Board Committees of the Company will be as follows:

BOARD OF DIRECTORS

Dr Hong Hai (Independent Director)
Mr Tan Soo Kiat (Non-Executive and Non-Independent Director)
Mr Koh Boon How, Kenneth (Non-Executive and Non-Independent Director)
(Alternate to Mr Tan Soo Kiat)
Mr Goh Kian Chee (Independent Director)

AUDIT AND RISK MANAGEMENT COMMITTEE

Mr Goh Kian Chee (Chairman)
Dr Hong Hai
Mr Tan Soo Kiat

Statement pursuant to Catalist Rule 704(7)

The Board has reviewed the information provided by Dr Hong Hai and considered him to be independent pursuant to Catalist Rule 704(7).

The Board has reviewed the information provided by Mr Tan Soo Kiat and considered him to be non-independent pursuant to Catalist Rule 704(7) as he has been providing corporate advisory services to the shareholders of Luye Medicals Group Pte. Ltd. (the new controlling shareholder of the Company).

NOMINATING COMMITTEE

Dr Hong Hai (Chairman)

Mr Goh Kian Chee

Mr Tan Soo Kiat

REMUNERATION COMMITTEE

Dr Hong Hai (Chairman)

Mr Goh Kian Chee

Mr Tan Soo Kiat

By Order of the Board

Secretary

Ms Foo Soon Soo

3 June 2015

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Xandar Capital Pte Ltd (the "Sponsor"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement including the correctness of any of the statements made, opinions expressed or reports contained in this announcement.

*Contact person for the Sponsor: Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd). Address: 3 Shenton Way, #24-02 Shenton House, Singapore 068805
Telephone number: (65) 6319 4954*